Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung SDI (006400) – DS Investment & Securities | Core Profitability Turnaround · Robust ESS Backlog · Humanoid Physical AI Expansion / 2026-07-31 Research
  • [Research] Alteogen (196170) – Daishin Securities | Validated ALT-B4 Platform · Keytruda SC Milestones Accelerate · Coverage Initiation / 2026-05-19 Research
  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Order Recovery · Plant Ramp-up · Earnings Growth / 2026-07-24 Research
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | AI MLCC Shortage · FC-BGA Margin Expansion · Earnings Direction / 2026-07-31 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Order Visibility · Production Expansion · Middle East Deliveries / 2026-08-07 Research
  • [Research] SK hynix (000660 / SKHY) – Hanwha | LTA · HBM · Earnings Sustainability / 2026-04-24 Research
  • [Research] Samsung Electro-Mechanics (009150) – iM Securities | LTA Transition · Specialty MLCC · Valuation Re-rating / 2026-07-01 Research

[Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Up-cycle · Large-Scale CapEx · Target Price Upgrade / 2026-07-08

Posted on July 8, 2026August 24, 2026 By ksb220805@gmail.com

Brokerage : Yuanta Securities

Analyst : Sunyoung Kou (Research Assistant: Seokmin Lim)

Investment Rating : BUY (Maintained)

Target Price : KRW 2,800,000 (Raised)

Core Momentum : Long-term earnings visibility and valuation premium expansion powered by simultaneous up-cycles across MLCC and FC-BGA alongside customer-backed mega CapEx expansions

📊 1. [Valuation & Key Financial Metrics]

  • Rating & Target Price: BUY (Maintained) / Target Price KRW 2,800,000 (Raised from KRW 2,200,000, +27.3%) (Closing price KRW 1,648,000 as of July 7, 2026; upside potential 70%)
  • Valuation Methodology: Applied a Target P/E multiple of 72.8x to 2027(E) EPS (15% premium over Ibiden’s 2027(E) P/E, reflecting superior growth diversity and durability from simultaneous MLCC and FC-BGA up-cycles)
  • Operating Profit Forecast Upgrades:
    • 2026 and 2027 operating profit forecasts raised by +3% and +19%, respectively
  • Key Financial Metrics & Forecast:
    • Revenue (KRW): 2024 KRW 10.294 Trillion → 2025 KRW 11.314 Trillion → 2026(E) KRW 13.361 Trillion → 2027(E) KRW 18.190 Trillion
    • Operating Profit (KRW): 2024 KRW 735.0 Billion → 2025 KRW 913.0 Billion → 2026(E) KRW 1.613 Trillion → 2027(E) KRW 3.573 Trillion
    • Net Profit (Controlling) (KRW): 2024 KRW 679.0 Billion → 2025 KRW 706.0 Billion → 2026(E) KRW 1.319 Trillion → 2027(E) KRW 2.885 Trillion
    • PER / PBR / ROE:
      • 2024: PER 15.6x, PBR 1.2x, ROE 8.2%
      • 2025: PER 17.5x, PBR 1.3x, ROE 7.7%
      • 2026(E): PER 93.8x, PBR 10.1x, ROE 12.1%
      • 2027(E): PER 42.8x, PBR 7.8x, ROE 20.4%
  • 2Q 2026 Forecast (2Q26E):
    • Revenue: KRW 3.240 Trillion (+16.4% YoY, +1.0% QoQ)
    • Operating Profit: KRW 418.0 Billion (+96.1% YoY, +48.9% QoQ, OPM 12.9%, beating consensus of KRW 391.0 Billion by +6.9%)
    • Net Profit (Controlling): KRW 332.0 Billion (+155.8% YoY, +33.2% QoQ)

🚀 2. [Market Opportunities & Business Outlook]

  • Segment Operational Drivers (2Q26E):
    • Component (MLCC): Rising mix of high-value server products driving blended ASP growth.
    • Package Solutions (FC-BGA): Operating leverage accelerating via ASP expansion and higher server revenue exposure.
    • Optics: Relatively sluggish demand, but minimal impact on consolidated earnings.
  • Order Momentum & Qualitative CapEx Shift:
    • MLCC Orders: Building on the KRW 1.55 Trillion silicon capacitor order, an additional KRW 450.0 Billion AI server MLCC contract was disclosed, proving the structural transition of MLCCs from commodity consumables into LTA-based critical hardware.
    • Mega Expansion: Recently disclosed investments in Sejong (KRW 0.8 Trillion) and Busan (KRW 1.5 Trillion) represent an unprecedented scale compared to historical annual CapEx of ~KRW 1 Trillion. Inflows of client co-funding signify a qualitative leap beyond basic CapEx spending.
  • Supply-Demand & Pricing Dynamics:
    • High order backlogs, lean inventories, and proactive Big Tech capacity bookings provide increasing visibility for broader price increases.

📝 Editor’s Comment (Perspective)

The analyst views Samsung Electro-Mechanics not as a cyclical supplier exposed to single-product volatility, but as an advanced hardware platform whose simultaneous up-cycles in MLCC and FC-BGA generate superior earnings growth and durability compared to single-segment global peers. This perspective emphasizes the structural strengthening of earnings visibility achieved through monthly disclosures of large-scale orders and customer-co-funded mega CapEx expansions.

To evaluate whether this investment thesis unfolds as anticipated, key verification checkpoints include achieving consensus-beating results in 2Q26, the sequential revenue recognition of disclosed silicon capacitor and AI server MLCC contracts, progress on Sejong (KRW 0.8 Trillion) and Busan (KRW 1.5 Trillion) facility expansions alongside client capital execution, and the broadening of channel price hikes into direct contracts. Progress on these factors can be tracked via upcoming quarterly earnings announcements, investor relations materials, and periodic regulatory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] Samsung Electro-Mechanics (009150) – Daishin Securities | Supply Shortage · High-End Mix · Earnings Upward Revisions / 2026-07-07
Next Post: [Research] Hanwha Ocean (042660) – Daishin | Early Offshore Revenue · Naval Defense Pipeline · Excessive Discount / 2026-07-09

Related Posts

  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Data Center ESS · Potential SDC Monetization · Operating Profit Turnaround / 2026-06-26 Research
  • [Research] Alteogen (196170) – Shinhan Securities | Keytruda SC Growth Accelerates · Favorable Contract Terms · Early June PGR Catalysts / 2026-05-11 Research
  • [Research] Hanwha Ocean (042660) – Yuanta | Merchant Vessel Margin · FX Gains · Earnings Differentiation / 2026-07-28 Research
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | High-Value Order Expansion · Valuation Re-rating · Capacity Utilization / 2026-07-02 Research
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | Silicon Capacitor · ASP Expansion · Valuation Re-rating / 2026-05-26 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ROE Expansion · Net Cash · Shareholder Returns / 2026-07-29 Research
  • [Research] LigaChem Biosciences (141080) – Yuanta Securities | Payload Chemistry · Safety Profile · Differentiation / 2025-05-22 Research
  • [IR] Samsung Electronics (005930) – Q4 2023 Earnings Presentation / 2024-01-31 IR Room
  • [Research] SK hynix (000660 / SKHY) – Hana | Commodity DRAM Pricing · LTA · Multiple Expansion / 2026-06-26 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Capacity Expansion · Peptide Entry · Guidance Upgrade / 2026-07-24 Research
  • [Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28 Research
  • [Research] LigaChem Biosciences (141080) – Eugene Investment & Securities | Pipeline Clinical Progression · Licensing Revenue · Earnings Turnaround / 2025-02-17 Research
  • [Research] SK hynix (000660 / SKHY) – iM Securities | Memory ASP · Server Demand · Earnings Upgrades / 2026-03-31 Research
  • [Research] Samsung SDI (006400/KS) – SK Securities | Prominent Base Effects · Conservative CapEx Management · Compelling Valuation / 2026-02-03 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme